首页> 美国卫生研究院文献>Bosnian Journal of Basic Medical Sciences >Efficacy of a bundle approach in preventing the incidence of ventilator associated pneumonia (VAP)
【2h】

Efficacy of a bundle approach in preventing the incidence of ventilator associated pneumonia (VAP)

机译:捆绑方法预防呼吸机相关性肺炎(VAP)的功效

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ventilator-associated pneumonia (VAP) is a potentially preventable iatrogenic illness that may develop following mechanical ventilation. A bundle for the prevention of VAP consists of different measures which may vary between institutions, and may include: elevation of the head of the bed, oral care with chlorhexidine, subglottic suctioning, daily assessment for extubation and the need for proton-pump inhibitors, use of closed suction systems, and maintaining endotracheal cuff pressure at 25 cmH2O. Our aim was to determine the efficacy of a VAP prevention bundle, consisting of the above-mentioned measures, by evaluating the incidence of VAP before (no-VAP-B group) and after (VAP-B group) the introduction of the bundle. We retrospectively evaluated the data for patients who were mechanically ventilated with an endotracheal tube, in the period between 1 September and 31 December 2014 (no-VAP-B group, n = 55, 54.5% males, mean age 67.8 ± 14.5 years) and between 1 January to 30 April 2015 (VAP-B group, n = 74, 62.1% males, mean age 64.8 ± 13.7 years). There were no statistically significant differences between no-VAP-B and VAP-B groups in demographic data, intensive care unit (ICU) mortality, hospital mortality, duration of ICU treatment, and duration of mechanical ventilation. No significant differences in the rates of VAP and early VAP (onset ≤7 days after intubation) were found between no-VAP-B and VAP-B groups (41.8% versus 25.7%, p = 0.06 and 10.9% versus 12.2%, p > 0.99, respectively). However, a significant decrease in the late VAP (onset >8 days after intubation) was found in VAP-B group compared to no-VAP-B group (13.5% versus 30.9%, p = 0.027). Overall, our results support the use of VAP prevention bundle in clinical practice.
机译:呼吸机相关性肺炎(VAP)是一种潜在可预防的医源性疾病,可能在机械通气后发展。预防VAP的方法包由不同的措施组成,不同的措施可能因机构而异,其中包括:抬高床头,口服洗必泰进行口腔护理,声门下抽吸,每日评估拔管以及是否需要质子泵抑制剂,使用封闭的抽吸系统,并将气管插管的压力保持在25 cmH2O。我们的目的是通过评估在引入VAP预防性捆绑之前(无VAP-B组)和之后(VAP-B组)的VAP发生率来确定由上述措施组成的VAP预防捆绑的有效性。我们回顾性评估了2014年9月1日至12月31日期间使用气管插管进行机械通气的患者的数据(无VAP-B组,n = 55,男性为54.5%,平均年龄为67.8±14.5岁), 2015年1月1日至4月30日之间(VAP-B组,n = 74,男性占62.1%,平均年龄64.8±13.7岁)。无VAP-B组和VAP-B组在人口统计学数据,重症监护病房(ICU)死亡率,医院死亡率,ICU治疗时间和机械通气时间方面无统计学差异。无VAP-B组和VAP-B组之间的VAP和早期VAP发生率(插管后≤7天)无显着差异(41.8%对25.7%,p = 0.06和10.9%对12.2%,p > 0.99)。但是,与无VAP-B组相比,VAP-B组的晚期VAP(插管后开始> 8天)显着减少(13.5%对30.9%,p = 0.027)。总体而言,我们的结果支持在临床实践中使用VAP预防捆绑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号